RZLT Stock Forecast: Rezolute, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$3.92
−6.67% on the day

The 11 Wall Street analysts covering Rezolute, Inc. hold a median 12-month price target of $10 — +155.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 42 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$465.6M
Ticker Nerd rank
42/ 100
Median analyst target
$10
Analysts covering
11
Revenue$0.0
Operating income−$17.4M
Net income−$16.2M
Free cash flow−$13.7M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+7.3%
1M
+5.9%
YTD
+66.1%
1Y
−59.4%
From 52W high
−64.2%
From 52W low
+180.0%
$1
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Rezolute, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
42/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
77
Value
63
Volatility
61
Growth
51
Issuance
45
Revisions
35
Quality
32
Momentum
25

Accruals (77): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (25): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

RZLT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RZLT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15Jan 26Apr 26Jul 26Oct 26RZLTHigh $15Median $10Low $6

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
11
Buy
0
Hold
0
Sell
$6
Low
$10
Median
$15
High

The green dot is the last close — the median target sits +155.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
17 Nov 2026WedbushMaintainsOutperform$6.00 → $10
6 Oct 2026Cantor FitzgeraldUpgradeOverweight—
6 Oct 2026CitizensMaintainsMarket Outperform$11 → $15
6 Oct 2026Lake StreetMaintainsBuy$9.00 → $12
30 Sept 2026Lake StreetInitiatesBuy$9.00
29 Sept 2026Craig-HallumUpgradeBuy$4.00 → $7.00
25 Sept 2026HC Wainwright & Co.MaintainsBuy$5.00 → $10
15 June 2026GuggenheimMaintainsBuy$6.00 → $11
3 June 2026CitizensUpgradeMarket Outperform—
3 June 2026Maxim GroupMaintainsBuy—
3 June 2026WedbushMaintainsOutperform—
2 June 2026BTIGMaintainsBuy—
2 June 2026HC Wainwright & Co.ReiteratesBuy—
14 May 2026Maxim GroupMaintainsBuy—
25 Mar 2026WedbushUpgradeOutperform—
8 Jan 2026BTIGReiteratesBuy—
8 Jan 2026WedbushMaintainsNeutral—
12 Dec 2025GuggenheimMaintainsBuy—
12 Dec 2025HC Wainwright & Co.MaintainsBuy—
20 Nov 2025BTIGReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for RZLT.

Market Radar

This page is one stock. Monday covers all of them.

RZLT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

RZLT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Rezolute, Inc. returned −59.4% against +6.9% for the S&P 500, dividends included.

RZLT vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26RZLTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RZLT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
6
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
4.4×

Cheaper than 21% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−66.9%

Higher than 18% of US stocks

Return on assets
−39.8%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Rezolute, Inc. has a market value of $465.6M and an enterprise value of $289.9M.

  • Revenue in the twelve months to 31 Mar 2026: $0.0.

  • Net income over the same four quarters: −$81.5M.

  • Diluted earnings per share, trailing twelve months: −$0.82.

  • Free cash flow in the twelve months to 31 Mar 2026: −$73.5M.

  • Shares outstanding: 96.3M.

  • Rezolute, Inc. employs 63 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

RZLT and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RZLTRezolute, Inc.$465.6M42
IRDOpus Genetics, Inc.$385.7M39
PHATPhathom Pharmaceuticals, Inc.$364.9M79
ASPEAspen Neuroscience, Inc.$361.2M0
AVTXAvalo Therapeutics, Inc.$390.9M29
PBYIPuma Biotechnology, Inc.$358.8M98
CADLCandel Therapeutics, Inc.$395.4M43

Take a look at RZLT’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Rezolute, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about RZLT

What is the RZLT stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Rezolute, Inc. have a median 12-month price target of $10, with estimates ranging from $6 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RZLT stock a buy right now?

Of the 11 analysts covering Rezolute, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rezolute, Inc. 42 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RZLT?

As at 21 Nov 2026, Rezolute, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (77 of 100).

Will RZLT stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +155.1% from the last close, and Ticker Nerd's factor model ranks Rezolute, Inc. 42 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RZLT stock forecast for 2030?

No analyst covering Rezolute, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RZLT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $15 over the next 12 months.

How has RZLT stock performed over the past year?

Rezolute, Inc. returned -59.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Rezolute, Inc. do?

Rezolute Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases associated with chronic glucose imbalance. Its lead program centers on ersodetug, an intravenously administered human monoclonal antibody being studied for congenital hyperinsulinism and other forms of hypoglycemia caused by hyperinsulinism.

Company

About Rezolute, Inc.

Rezolute Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases associated with chronic glucose imbalance. Its lead program centers on ersodetug, an intravenously administered human monoclonal antibody being studied for congenital hyperinsulinism and other forms of hypoglycemia caused by hyperinsulinism. The company’s pipeline also includes additional candidates aimed at conditions such as diabetic macular edema, reflecting a broader focus on endocrine and metabolic disorders. Rezolute Inc. works at the intersection of rare disease research and targeted drug development, with its programs designed to address serious conditions that have limited treatment options. Based in Redwood City, California, the company plays a specialized role in the biopharmaceutical market by advancing therapies for ultra-rare pediatric and metabolic diseases.

CEO Mr. Nevan Charles Elam J.D. · 63 employees · United States · https://www.rezolutebio.com